OCBCO
AMLX icon

Oversea-Chinese Banking Corp (OCBC)’s Amylyx Pharmaceuticals AMLX Stock Holding History

Oversea-Chinese Banking Corp (OCBC)’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-16,785
Closed -$620K – 320
2022
Q4 		$620K Buy
+16,785
New +$596K 0.04% 200

Other funds holding AMLX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Oversea-Chinese Banking Corp (OCBC)'s AMLX Position: Q1 2023 in Review

Oversea-Chinese Banking Corp (OCBC) sold out of Amylyx Pharmaceuticals (AMLX) in Q1 2023, closing a stake of 16,785 shares — an estimated $620K sold.

Oversea-Chinese Banking Corp (OCBC) first reported a position in AMLX in Q4 2022 and held it in 1 quarter. The position peaked at $620K in Q4 2022. 147 funds tracked by Wall St. Rank hold AMLX as of Q1 2023.

  • Oversea-Chinese Banking Corp (OCBC) reported no remaining Amylyx Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Oversea-Chinese Banking Corp (OCBC) sold 16,785 Amylyx Pharmaceuticals shares in Q1 2023, an estimated $620K.
  • Oversea-Chinese Banking Corp (OCBC) first reported a position in Amylyx Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • Oversea-Chinese Banking Corp (OCBC)'s Amylyx Pharmaceuticals position peaked at $620K in Q4 2022.
  • 147 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2023.

Based on Oversea-Chinese Banking Corp (OCBC)'s 13F filing for Q1 2023, filed 4 May 2023.